Drug Trial Radar · NCT02899364
Sodium Thiosulfate to Preserve Cardiac Function in STEMI
Last checked: Nov 19, 2026Latest source record: Sep 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
380
Planned (sponsor's estimate)
Start
Jul 20, 2018
Primary completion
Jun 25, 2021
Study completion Mar 2023
Sponsor
- Lead sponsor
- University Medical Center GroningenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 14, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Rationale: Timely and effective reperfusion by primary percutaneous coronary intervention (PPCI) is currently the most effective treatment of ST-segment elevation myocardial infarction (STEMI). However, permanent myocardial injury related to the ischemia and subsequent reperfusion is observed in the vast majority (88%) of patients and harbours a risk of heart failure development. Administration of hydrogen sulfide (H2S) has been shown to protect the heart from "ischemia reperfusion injury" in various experimental models. Data in humans suggests that the H2S-releasing agent sodium thiosulfate (STS) can be administered safely. Objective: to evaluate the efficacy and safety of STS compared to placebo treatment on myocardial infarct size in patients presenting with STEMI and treated with PCI Study design: a multicenter, double blind, randomized controlled clinical trial. A total of 380 patients, aged 18 years and above, undergoing primary PCI for a first STEMI and deemed amenable, by the investigator, to be treated with STS 12.5g intravenously (i.v.) or matched placebo immediately after arrival at the catheterization laboratory (cath-lab) and a repeated dose administered 6 hours after the first dose, on top of standard treatment. Primary endpoint is infarct size as measured with cardiac magnetic resonance imaging (CMR-imaging) 4 months after randomization.
Conditions
- Myocardial Infarction
- Heart Failure
Interventions
Sodium thiosulfateDrug
see description under experimental arm
Sodium chloride 0.9%Drug
see description under placebo comparator arm
primary percutaneous coronary interventionProcedure
Primary treatment of the ischemia-related coronary artery is left to discretion of the operator and might consist of thrombus aspiration, balloon inflation and stent implantation. Additional balloon angioplasty or stenting of the culprit or other lesions will be performed when necessary.
cardiac magnetic resonance imagingOther
CMR-imaging will be used for assessment of infarct size, left ventricular function, quantification of myocardial scar and diffuse myocardial fibrosis. CMR-imaging examinations will be performed on a 3 Tesla scanner using a phased array cardiac receiver coil at 4 months after randomization according to standard protocols. The full study protocol lasts approximately 45 minutes and includes anatomy and function, LGE and T1-mapping.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Myocardial infarct size as measured with late gadolinium enhancement cardiac magnetic resonance imaging.Time frame: 4 months after randomization
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University Medical Centre Groningen
Groningen, Netherlands
University Medical Center Utrecht
Utrecht, Netherlands
Treant Scheper Hospital
Emmen, Drenthe, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.